← All trials
NCT04747236
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Feb 10, 2021
- Last posted
- Mar 19, 2021
- Enrollment
- 74
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of VirginiaLead sponsor
- University of VirginiaReponsible party - principal investigator
- University of VirginiaOverall official - principal investigator
- CelgeneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.